直接口服抗凝剂和维生素K拮抗剂:在血栓损伤中的作用、安全性和适应症

Thrombectomy - Recent Advances in Ischaemic Damage Treatment [Working Title] Pub Date : 2021-12-23 DOI:10.5772/intechopen.100514

Mohammed Aldhaeefi, Abdulrahman I. Alshaya, Khalid bin Saleh, Omar A. Alshaya, H. Badreldin

{"title":"直接口服抗凝剂和维生素K拮抗剂:在血栓损伤中的作用、安全性和适应症","authors":"Mohammed Aldhaeefi, Abdulrahman I. Alshaya, Khalid bin Saleh, Omar A. Alshaya, H. Badreldin","doi":"10.5772/intechopen.100514","DOIUrl":null,"url":null,"abstract":"This chapter is intended to discuss the available oral anticoagulants, including vitamin K antagonists and the Direct Oral Anticoagulants such as dabigatran, apixaban, rivaroxaban, and edoxaban. It will review their basic pharmacology, pharmacokinetics, pharmacodynamics, dosage forms, clinical indications, and place in therapy. Finally, this chapter will also discuss the currently available reversal agents.","PeriodicalId":132087,"journal":{"name":"Thrombectomy - Recent Advances in Ischaemic Damage Treatment [Working Title]","volume":"14 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2021-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Direct Oral Anticoagulants and Vitamin K Antagonists: Role in Thrombotic Damage, Safety, and Indications\",\"authors\":\"Mohammed Aldhaeefi, Abdulrahman I. Alshaya, Khalid bin Saleh, Omar A. Alshaya, H. Badreldin\",\"doi\":\"10.5772/intechopen.100514\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"This chapter is intended to discuss the available oral anticoagulants, including vitamin K antagonists and the Direct Oral Anticoagulants such as dabigatran, apixaban, rivaroxaban, and edoxaban. It will review their basic pharmacology, pharmacokinetics, pharmacodynamics, dosage forms, clinical indications, and place in therapy. Finally, this chapter will also discuss the currently available reversal agents.\",\"PeriodicalId\":132087,\"journal\":{\"name\":\"Thrombectomy - Recent Advances in Ischaemic Damage Treatment [Working Title]\",\"volume\":\"14 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-12-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Thrombectomy - Recent Advances in Ischaemic Damage Treatment [Working Title]\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5772/intechopen.100514\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Thrombectomy - Recent Advances in Ischaemic Damage Treatment [Working Title]","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5772/intechopen.100514","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

本章旨在讨论可用的口服抗凝剂，包括维生素K拮抗剂和直接口服抗凝剂，如达比加群、阿哌沙班、利伐沙班和依多沙班。它将回顾他们的基本药理学，药代动力学，药效学，剂型，临床适应症，并在治疗中的位置。最后，本章还将讨论目前可用的逆转剂。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Direct Oral Anticoagulants and Vitamin K Antagonists: Role in Thrombotic Damage, Safety, and Indications

This chapter is intended to discuss the available oral anticoagulants, including vitamin K antagonists and the Direct Oral Anticoagulants such as dabigatran, apixaban, rivaroxaban, and edoxaban. It will review their basic pharmacology, pharmacokinetics, pharmacodynamics, dosage forms, clinical indications, and place in therapy. Finally, this chapter will also discuss the currently available reversal agents.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Thrombectomy - Recent Advances in Ischaemic Damage Treatment [Working Title]

自引率

0.00%

发文量